Diagens Biotechnology Releases Universal Medical Imaging Large Model, Covering 90% of Clinical Scenarios

Deep News
Sep 26

On the morning of September 26, during the debut showcase session of the Fourth Global Digital Trade Expo, Diagens Biotechnology unveiled its self-developed iMedImage™, the world's largest-parameter universal medical imaging large model. The model completed pre-training based on 80 million data points, supports 19 modalities including chromosomes, CT, and MRI, covers over 90% of clinical scenarios, and demonstrates strong universality and high scalability.

At the event, the Diagens Biotechnology team demonstrated a "zero-code, automated" model training process, showcasing comprehensive capabilities from data import to model generation. According to reports, compared to traditional specialized models, iMedImage™ requires only hundreds of images and several days of training to build disease-specific models, significantly reducing data dependency and cutting development costs by over 90%.

The model has previously received the Sullivan Global Medical Imaging Foundation Large Model Innovation Award. A representative from Diagens Biotechnology stated that iMedImage™, leveraging a "Model as a Service" platform, significantly lowers the application threshold for AI in medical research and clinical practice.

During the exhibition, Diagens Biotechnology also signed strategic cooperation agreements with Wutong Tree, Inspur Group, and ZTE Corporation to jointly advance the research transformation and industrial implementation of AI medical imaging.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10